Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present KemPharm, Inc. (NASDAQ: KMPH).

Full DD Report for KMPH

You must become a subscriber to view this report.


Recent News from (NASDAQ: KMPH)

FDA OKs first non-opioid treatment for opioid withdrawal
The FDA approves privately held US WorldMeds LLC's Lucemyra (lofexidine hydrochloride) for the management of opioid withdrawal symptoms in adults who abruptly discontinue opioids. More news on: Endo International plc, Allergan plc, Johnson & Johnson, Healthcare stocks news, Read ...
Source: SeekingAlpha
Date: May, 16 2018 16:44
KemPharm: Patients Not Liking Their Drugs Is Great News
On November 25th, 2017, I first wrote about a small biotech called KemPharm ( KMPH ) and emphasized the importance of the ADHD portion of KemPharm's pipeline. I wrote about Apadaz and the pain portion of KemPharm's pipeline as somewhat of a liability, but believed that the substantial potent...
Source: SeekingAlpha
Date: May, 14 2018 02:50
KemPharm's (KMPH) CEO Travis Mickle on Q1 2018 Results - Earnings Call Transcript
KemPharm (INDB) Q1 2018 Earnings Conference Call May 10, 2018 04:30 PM ET Executives Dan Cohen - Executive Vice President Travis Mickle - President, Chief Executive Officer LaDuane Clifton - Chief Financial Officer Analysts Randall Stanicky – RBC Capital Markets De...
Source: SeekingAlpha
Date: May, 11 2018 21:38
KemPharm misses by $1.07
KemPharm (NASDAQ: KMPH ): Q1 EPS of -$1.77 misses by $1.07 . More news on: KemPharm, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 10 2018 16:31
KemPharm Announces Positive, Topline Results from an Intravenous Human Abuse Potential Trial with KP415 Prodrug; Reports Q1 2018 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Intravenous Human Abuse Potential Trial with KP415 Prodrug (KP415.A03) Clinical Findings: Following intravenous administration in recreational stimulant abusers, KP415 ...
Source: GlobeNewswire
Date: May, 10 2018 16:05
How To Play 'Am I Diversified?' In The Pharma/Biotech Space
Background Many investors (including myself) regularly watch or listen to the show "Mad Money" by Jim Cramer on CNBC. As with any celebrity, Mr. Cramer tends to be polarizing, with some loving him and some reveling in pointing out when he is wrong. Rather than focusing on his individual stoc...
Source: SeekingAlpha
Date: May, 03 2018 00:54
KemPharm, Inc. to Report First Quarter 2018 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for  May 10, 2018, 4:30 p.m. ET CORALVILLE, Iowa, May 01, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary pro...
Source: GlobeNewswire
Date: May, 01 2018 07:30
Opioid prescriptions dropped 12% in 2017
Opioid prescriptions dropped 12% in 2017, according to a report from the IQVIA Institute for Human Data Science. More news on: Johnson & Johnson, Endo International plc, Teva Pharmaceutical Industries Limited, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: April, 26 2018 03:18
Blog Exposure - VBI Vaccines Announced Dosing of Last Patient in PROTECT Phase-3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine
Stock Monitor: KemPharm Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 23, 2018 / Active-Investors.com has just released a free research report on VBI Vaccines Inc. (NASDAQ: VBIV ). If you want access to this report all you need to do is sign up now by clicking the following...
Source: ACCESSWIRE IA
Date: April, 23 2018 07:30
U.S. opioid prescriptions down 12% last year, largest drop in 25 years
According to IQVIA ( IQV -0.8% ), U.S. opioid prescriptions declined 12% in 2017, the largest annual drop in 25 years as doctors respond to the opioid crisis. More news on: IQVIA Holdings, Inc., Insys Therapeutics, Inc., Johnson & Johnson, Healthcare stocks news, News on ETFs, ...
Source: SeekingAlpha
Date: April, 19 2018 11:25

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-216.356.306.456.2057,985
2018-05-186.206.406.406.1039,511
2018-05-176.406.106.456.0051,509
2018-05-166.256.4256.506.2070,876
2018-05-155.956.2256.555.95150,495

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-2118,40328,75763.9949Short
2018-05-1813,62527,41349.7027Short
2018-05-177,88917,61944.7755Short
2018-05-1625,84349,32952.3891Short
2018-05-1531,21285,13736.6609Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on KMPH.


About KemPharm, Inc. (NASDAQ: KMPH)

Logo for KemPharm, Inc. (NASDAQ: KMPH)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $89,118,603 - 05/11/2018
  • Issue and Outstanding: 15,104,848 - 03/28/2018

 


Recent Filings from (NASDAQ: KMPH)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 12 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 12 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 30 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 23 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: KMPH)

Daily Technical Chart for (NASDAQ: KMPH)


Stay tuned for daily updates and more on (NASDAQ: KMPH)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: KMPH)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in KMPH is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of KMPH and does not buy, sell, or trade any shares of KMPH. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/